JNJ - Johnson & Johnson
| Previous Close | 132.07 |
| Open | 132.25 |
| Bid | 130.01 x 900 |
| Ask | 130.25 x 1100 |
| Day's Range | 130.19 - 132.39 |
| 52 Week Range | 121.00 - 148.99 |
| Volume | 8,340,239 |
| Avg. Volume | 7,064,258 |
| Market Cap | 345.981B |
| Beta (3Y Monthly) | 0.76 |
| PE Ratio (TTM) | 21.64 |
| EPS (TTM) | 6.02 |
| Earnings Date | Oct 15, 2019 |
| Forward Dividend & Yield | 3.80 (2.88%) |
| Ex-Dividend Date | 2019-08-26 |
| 1y Target Est | 149.28 |
- Business Wire•yesterday
JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $417 million award to one California plaintiff in August 2017 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of JNJ earnings conference call or presentation 16-Jul-19 12:30pm GMT
Q2 2019 Johnson & Johnson Earnings Call
- Zacks•2 days ago
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
- Benzinga•2 days ago
Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts
Canaccord Genuity analyst Jason Mills maintained a Buy rating on Intuitive Surgical and lifted the price target from $575 to $610. Stifel analyst Rick Wise rates the shares a Buy, with a $570 price target. Morgan Stanley analyst David Lewis reiterated an Overweight rating and $620 price target.
- Zacks•2 days ago
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
- Zacks•2 days ago
Dow 30 Stock Roundup: MSFT, JPM, IBM, JNJ, GS Earnings Impress
The Dow endured a volatile week, primarily due to renewed trade tensions, after gaining strongly earlier this month
- Zacks•3 days ago
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
- TheStreet.com•3 days ago
Jim Cramer: Looking for Netflix Action? Don't Be a Hero
Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.
- Zacks•3 days ago
Top Stock Reports for Johnson & Johnson, NextEra & Deere
Top Stock Reports for Johnson & Johnson, NextEra & Deere
- Market Realist•3 days ago
Litigation Looms in the Wake of JNJ’s Solid Q2 Earnings
Johnson & Johnson (JNJ) reported its second-quarter earnings results before the market opened on Tuesday.
- Motley Fool•3 days ago
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.
- Investor's Business Daily•4 days ago
These 4 Medical Stocks Could Benefit From J&J Earnings — Here's Why
JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology. Penumbra works in stroke treatment.
- Benzinga•4 days ago
FlexShares Makes A Big Low Vol ETF Splash
FlexShares, a major purveyor of smart beta exchange traded funds, is throwing its weight around in the low volatility ETF arena in a big way with the introduction of three funds that combine that investment ...
- Benzinga•4 days ago
After Earnings Beat, Wall Street Talks Johnson & Johnson Litigation Risk
Johnson & Johnson (NYSE: JNJ) shares are down 2% since the company reported a second-quarter earnings beat on Tuesday morning. Johnson & Johnson reported a 42% increase in net profit in the quarter. The company also reiterated its full-year earnings guidance and raised its sales forecast, but investors seem increasingly concerned about the potential negative impacts of opioid and talc litigation.
- Zacks•4 days ago
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
- Financial Times•4 days ago
WHO declares emergency over Ebola epidemic in Congo
The World Health Organization has declared an international emergency over the Ebola epidemic in the Democratic Republic of Congo, which has killed more than 1,600 people over the past year and shows no sign of declining. Dr Tedros Adhanom Ghebreyesus, WHO director-general, announced that the outbreak was now a “public health emergency of international concern” after a meeting of the UN-affiliated organisation’s emergency committee in Geneva. “We need to work together in solidarity with the DRC to end this outbreak,” said Dr Tedros.
- MarketWatch•4 days ago
Opioid makers dumped 76 billion pills onto U.S. market over 7 critical years, data shows
Newly released federal data shows how drugmakers and distributors increased shipments of opioid painkillers across the U.S. as the nation’s addiction crisis accelerated from 2006 to 2012.
- GuruFocus.com•5 days ago
Johnson & Johnson Registers 2nd-Quarter Earnings Beat
Shares slide on mounting legal costs Continue reading...
- Investor's Business Daily•5 days ago
Here's Why J&J Stock Is Sliding Despite A Second-Quarter Beat
JNJ stock slipped Tuesday after Dow Jones component Johnson & Johnson topped Wall Street's second-quarter earnings and revenue forecasts, but kept its full-year profit guidance intact.
- Reuters•5 days ago
US STOCKS-Wall Street slips as bank earnings, Trump trade comments weigh
U.S. stocks edged lower on Tuesday as quarterly results from banks added to concerns about lower interest rates dampening their profits, while comments from U.S. President Donald Trump on trade also dragged down Wall Street's major indexes. Johnson & Johnson shares slipped 1.6% after the diversified healthcare company warned that competition from generic and copycat drugs could impact its third-quarter results.
- Yahoo Finance•5 days ago
Johnson & Johnson CFO on the opioid crisis: 'We don’t believe we were the cause'
Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).
- InvestorPlace•5 days ago
Dow Jones Today: Earnings Disappointments
With some marquee earnings reports out today, it would have been reasonable to expect some more action out of the major U.S. equity benchmarks. By the time the closing bell sounded, though, Tuesday had all the appearances of just another boring summertime trading day.Source: Shutterstock The Nasdaq Composite fell 0.43% while the S&P 500 gave up 0.34%. The Dow Jones Industrial Average was mostly flat, settling down 0.09%.Arguably adding to the disappointment that was Tuesday's broader market action was that there was some encouraging economic data out earlier in the day. Retail sales rose for a fourth consecutive month in June, indicating that one of the primary drivers of the U.S. economy, the consumer, remains sturdy. And that data point does not even include Amazon's (NASDAQ:AMZN) Prime Day, which shattered records.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip Prime Day spanned into today and some analysts forecast $5 billion or more in sales for Amazon, easily topping 2018's Prime Day haul of $3.2 billion. Bottom line: the consumer is in good health and that should be meaningful for riskier assets going forward.Now let's get into some of those earnings reports. Boffo BanksDow component JPMorgan Chase (NYSE:JPM), the largest U.S. bank, was one of the blue-chip index's standouts Tuesday, gaining 1.06%, after the company said it earned $2.59 a share on revenue of $29.57 billion. Analysts were expecting earnings of $2.51 per share and revenue of $28.9 billion.As was noted here yesterday, net interest margins could become problematic for banks if interest rates decline. To that end, JPMorgan pared its 2019 net interest margin guidance to $57.5 billion from $58 billion.Goldman Sachs (NYSE:GS) was another Dow leader today, adding 1.87% after the investment bank said it earned $5.81 a share on revenue of $9.46 billion. Analysts expected earnings of $4.89 per share on revenue of $8.83 billion."Institutional client revenue, which includes trading, slipped 3%, while investment banking revenue was down 9%. However, revenue from the bank's investing and lending business rose 16%, its highest quarterly performance in eight years," according to Reuters. A Beat, but DisappointmentPharmaceuticals giant Johnson & Johnson (NYSE:JNJ) slipped 1.64% despite delivering an upbeat second-quarter report. The healthcare company said it earned $2.58 per share on sales of $20.56 billion. Wall Street expected a profit of $2.46 per share on sales of $20.29 billion.More importantly, JNJ boosted its 2019 sales forecast, excluding currency movement, to $82.4 billion to $83.2 billion, from an original range of $82 billion to $82.8 billion and the stock still declined. Credit Suisse resumed coverage of JNJ today with a $156 price target, implying significant upside from current levels. Quick AsideOnce again, Dow Inc (NYSE:DOW) was one of the Dow's best performers today, surging 2.73%. The stock has been on a torrid pace as of late. Investors considering the chemical maker may want to go here to mull over some of the bullish catalysts for the name. Bottom LineToday's earnings reports were mostly solid. It's certainly hard to quibble with JNJ raising revenue guidance, but plenty of tests remain this week and trade is clearly still an issue. President Donald Trump confirmed as much, noting the U.S. and China still have a long way to go on trade.Thursday is potentially significant day on the earnings front with Microsoft (NASDAQ:MSFT) and UnitedHealth (NYSE:UNH) among the Dow components reporting. Investors looking for a particular factor to watch should consider profit margins, regardless of company or sector."Many investors and analysts say a potential decline in profit margins--a measurement of how much a company's sales exceed its costs--is more worrisome than contracting earnings in the second quarter," according to the Wall Street Journal.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post Dow Jones Today: Earnings Disappointments appeared first on InvestorPlace.
- Yahoo Finance•5 days ago
Stocks slip slightly amid trade remarks, earnings season
U.S. stocks were mixed Tuesday afternoon as investors digested a wave of signals from officials over U.S.-China trade relations and monetary policy, along with an influx of corporate earnings results and economic data.
- Reuters•5 days ago
US STOCKS-S&P 500 edges lower after mixed bank earnings, Trump comments
